Skip to main navigation

Our Science
Investors & Media
Investor Relations
Who We Are
Contact
Patients & Caregivers

Press Releases

Year

Verastem Oncology Outlines Key 2024 Strategic Priorities and Upcoming Catalysts for Advancing Avutometinib and Defactinib and Broader Pipeline in RAS Pathway-Driven Cancers

January 29, 2024

Verastem Oncology Granted Fast Track Designation for Combination of Avutometinib and Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)

January 18, 2024

Verastem Oncology to Participate in the B. Riley Securities 4th Annual Oncology Conference

January 11, 2024

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 5, 2024

Pagination

First page
Previous page
Page 1
Page 2
Page 3
Current page 4

Terms of Use
Copyright Statement
Privacy Policy
Contact

© 2025 Verastem, Inc. All Rights Reserved.